The Australian Alport Syndrome Therapeutics market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Alport syndrome is a rare genetic disorder caused by the gene mutation of COL4A3, COL4A4, or COL4A5 & characterized by progressive kidney disease and abnormalities of the inner ear and the eye. The hallmark of the disease is the presence of blood in the urine (haematuria) early in life, with progressive decline in kidney function (kidney insufficiency) that ultimately results in kidney failure, especially in affected males. Both males and females with ARAS develop kidney failure, often in the teenage years or early adulthood. ADAS tends to be a slowly progressive disorder in which renal insufficiency does not develop until well into adulthood. Individuals with Alport syndrome can also develop progressive hearing loss of varying severity and abnormalities of the eyes that usually do not result in impaired vision.



Market Growth Drivers

Alport syndrome is a major cause of kidney disease among the patient population. The rise in the prevalence of genetic disorders is likely to augment the Alport syndrome market. High investments by the key players and initiatives by governments for research and development of drugs for managing Alport syndrome and its symptoms are likely to propel the Alport syndrome market. Hence, faster adoption and availability of diagnostic tests across the market are anticipated to augment the Alport syndrome market. However, low awareness about the syndrome and its lower diagnosis rates act as major restraints of the Alport syndrome market.